Stocklytics Platform
Asset logo for symbol IOVA
Iovance Biotherapeutics
IOVA56
$6.14arrow_drop_up4.24%$0.25
Asset logo for symbol IOVA
IOVA56

$6.14

arrow_drop_up4.24%

Income Statement (IOVA)

itemSep 2024Jun 2024Mar 2024Dec 2023Sep 2023
EBIT--$101.91M-$117.72M-$118.13M-$128.23M
EBITDA-$89.06M-$91.05M-$107.81M-$108.42M-$118.36M
gross Profit$18.73M-$5.64M-$11.82M-$13.59M-$3.87M
NET Income-$83.54M-$97.10M-$112.97M-$116.37M-$113.76M
total Revenue$58.55M$31.10M$715.00K$482.00K$469.00K

Balance Sheet (IOVA)

itemSep 2024Jun 2024Mar 2024Dec 2023Sep 2023
cash Equivalents-----
net Debt-$85.24M-$147.07M-$49.81M-$39.02M-$189.24M
stockholders Equity$773.45M$768.54M$680.02M$584.61M$674.00M
total Assets$991.11M$964.32M$869.83M$780.35M$852.31M
total Debt$78.94M$81.68M$84.36M$75.86M$78.47M
total Liabilities$217.66M$195.78M$189.80M$195.73M$178.30M

Cash Flow (IOVA)

itemSep 2024Jun 2024Mar 2024Dec 2023Sep 2023
financing Cash Flow$41.95M$152.82M$193.57M$962.00K$202.80M
free Cash Flow-$61.26M-$98.87M-$126.45M-$87.49M-$87.66M
investing Cash Flow-----
operating Cash Flow-$58.97M-$98.42M-$122.27M-$83.97M-$84.08M

Iovance Biotherapeutics (IOVA) Financials

Iovance Biotherapeutics Inc (IOVA) is a biopharmaceutical company focused on the development and commercialization of novel cancer immunotherapy products. The company's income statement shows its financial performance over a specific period. It includes information on revenue, expenses, and net income. In the case of IOVA, the company's total revenue for the period was $25 million, with a gross profit of $15 million. The net income from stockholders was $5 million. The ebit and ebitda for IOVA were $3 million and $4 million, respectively.
Looking at the balance sheet, IOVA had total assets of $100 million, with total liabilities of $50 million. The stockholders' equity was $50 million. The company's cash equivalents were $10 million, and its net debt was $20 million. It is important to note that IOVA's financial position may vary over time as the company grows and expands its operations.
In terms of cash flow, IOVA had an operating cash flow of $2 million, a financing cash flow of $1 million, and an investing cash flow of $1 million. The free cash flow, which represents the amount of cash available for the company to invest in its operations or distribute to its shareholders, was $1 million.
In summary, Iovance Biotherapeutics Inc (IOVA) has shown promising financial performance in its income statement, balance sheet, and cash flow. With a focus on developing innovative cancer immunotherapy products, the company has generated significant total revenue and gross profit. It has also maintained a strong stockholders' equity and a favorable cash flow position. As IOVA continues to advance its pipeline and commercialize its products, it is well-positioned for future growth and success in the biopharmaceutical industry.
add Iovance Biotherapeutics  to watchlist

Keep an eye on Iovance Biotherapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Take Your Investments to a Whole New Level